Evidence map›Paper›PMID 34447239›Full record

ArticleMolecular vision2021

Amniotic membrane conditioned medium (AMCM) reduces inflammatory response on human limbal myofibroblast, and the potential role of lumican.

Alfredo Domínguez-López, Fátima Sofía Magaña-Guerrero, Beatriz Buentello-Volante, Luis Antonio Bautista-Hernández, Juan Pablo Reyes-Grajeda, Víctor Manuel Bautista-de Lucio, Yonathan Garfias

Open access · greenAbstract read
In one paragraph

Article in Molecular vision, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.6field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 4 citations in OpenAlex.

  1. Observational
  2. Review
  3. Topical Losartan: Practical Guidance for Clinical Trials in the Prevention and Treatment of Corneal Scarring Fibrosis and Other Eye Diseases and Disorders.Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics · 2023
    Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

Alfredo Domínguez-LópezResearch Unit, Institute of Ophthalmology Conde de Valenciana Foundation, Mexico City, Mexico.
Fátima Sofía Magaña-GuerreroResearch Unit, Institute of Ophthalmology Conde de Valenciana Foundation, Mexico City, Mexico.
Beatriz Buentello-VolanteResearch Unit, Institute of Ophthalmology Conde de Valenciana Foundation, Mexico City, Mexico.
Luis Antonio Bautista-HernándezResearch Unit, Institute of Ophthalmology Conde de Valenciana Foundation, Mexico City, Mexico.
Juan Pablo Reyes-GrajedaMedical Proteomics Unit, Instituto Nacional de Medicina Genómica, Mexico City, Mexico.
Víctor Manuel Bautista-de LucioResearch Unit, Institute of Ophthalmology Conde de Valenciana Foundation, Mexico City, Mexico.
Yonathan GarfiasResearch Unit, Institute of Ophthalmology Conde de Valenciana Foundation, Mexico City, Mexico.
Institute of Ophthalmology · MXCentre National de la Recherche Scientifique · FRNational Institute of Genomic Medicine · MX

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: Viral infections such as herpetic keratitis (HSK) activate the innate immune response in the cornea triggering opacity and loss of vision. This condition is performed mainly by myofibroblasts that exacerbate secretion of inflammatory cytokines. Amniotic membrane transplantation (AMT) reduces ocular opacity and scarring inhibiting secretion of inflammatory cytokines and proliferation of myofibroblasts. We previously reported that the amniotic membrane (AM) favors an anti-inflammatory microenvironment inhibiting the secretion of inflammatory cytokines, expression of innate immune receptors, and translocation of nuclear NF-κB on human limbal myofibroblasts (HLMs). The aim of the present study was to determine whether the soluble factors of the AM decrease the immune response of HLMs stimulated with polyinosinic-polycytidylic acid sodium salt (poly I:C). Methods: The AM was incubated in Dulbecco's modified eagle medium (DMEM)/F12, and the supernatant was collected to obtain amniotic membrane conditioned medium (AMCM). HLMs were isolated from cadaveric sclera-corneal rims. HLMs were cultured in DMEM/F12 or AMCM and stimulated or not with poly I:C (10 µg/ml) for 12 h to analyze synthesis of CCL2, CCL5, CXCL10, MDA5, RIG-1, and TLR3 or for 2 h to analyze translocation of nuclear NF-kB, IRF3, and IRF7. The proteins contained on AMCM were analyzed by matrix assisted laser desorption ionization-time of flight mass spectrometry (MALDI-TOF MS), and the acquired peptide ions were analyzed with the Mascot program using both National Center for Biotechnology Information (NCBI) and expressed sequence tag (EST) databases. Results: AMCM downregulated the mRNA levels of CCL2, CCL5, CXCL10, MDA5, RIG-1, and TLR3. In addition, AMCM decreased secretion of CCL2, CCL5, and CXCL10 and translocation of nuclear NF-κB. Interestingly, AMCM increased translocation of nuclear IRF3 and synthesis and secretion of type I IFN-β. We also identified small leucine-rich proteoglycan lumican in the AMCM. The administration of Conclusions: These results suggest that the AM can trigger an anti-inflammatory response on HLMs through soluble factors, and that lumican could play an important role in these effects.

Indexed as

AmnionCells, CulturedCulture Media, ConditionedCytokinesEnzyme-Linked Immunosorbent AssayFluorescent Antibody Technique, IndirectHumansImmunity, InnateInflammationLimbus CorneaeLumicanMyofibroblastsNF-kappa BPhosphorylationPoly I-CCulture Media, ConditionedCytokinesLumicanNF-kappa BPoly I-C

Identifiers

PMID34447239
PMCPMC8370574
OpenAlexW3194720209

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.